Johnson & Johnson introduced its vaccine against coronavirus and says that it is 66% effective in preventing COVID-19. They tried it on a global trial against multiple variants and proved its ability to act as a weapon to tackle the coronavirus. Johnson & Johnson attempted the trial of nearly 44,000 volunteers and tested the level of protection against severe and moderate COVID-19 varied from 57% in South Africa, 72% in the United States, and 66% in Latin America.
In the pivotal trial of Pfizer/BioNTech, they set a high bar by proving 95% effective in preventing symptomatic illness. These trials were mainly conducted in the United States before the emergence of new variants. Johnson & Johnson is mainly trying to prevent moderate to severe COVID-19 and found that it is 85% effective in stopping severe disease and preventing hospitalization across all geographies.
The next step taken by the J&J is trying to get the approval for the emergency use authorization from the U.S. Food Drug Administration next week. The main plan is to deliver 1 billion doses in 2021 and will produce the vaccine in the United States, Europe, South Africa, and India. J & J is planning for the immediate availability of the vaccines and it is depending upon the emergency approval. The invention of the vaccine is considered a great step to recover the desperations of many countries. None of the vaccine recipients were included in the J&J trial.
Most of the studies show the presence of the mutated virus in South Africa. South African Variants and such places are a key target of the vaccines. All the vaccines are primarily focusing on the reducing efficacy of the virus. COVID-19 and its presence are disrupting the entire world. The major learning is that different efficacy in a different part of the world. As a part of the sub study conducted in South Africa, the vaccine is 89% effective at preventing severe diseases. 95% of cases were reported due to the infections with the South African trial. Johnsons & Johnsons uses the technique of uses the cold virus to introduce coronavirus protein into cells in the body and trigger immune response. The Pfizer/BioNTech and Moderna uses a new technology which is named RNA (mRNA). Anyway, J&J introduced this vaccine at the correct time and the world is waiting for further proceedings.
Follow and connect with us on Facebook, Linkedin & Twitter
